



# BIOFIL CHEMICALS & PHARMACEUTICALS LTD.

Regd. Office : 11/12, Sector-E, Sanwer Road, Industrial Area, Indore - 452 015. Fax : 0731-2723017  
Tel. : 0731-2723016, 4066216 E-mail : biofilchemicals@yahoo.com / bcplcompliance@gmail.com  
Factory : Plot No. 8, Sector - IV, Kheda Industrial Area, Pithampur Distt. Dhar (M.P.)

Admn. Office : B-12/B, Industrial Estate, Pologround, Indore - 452 015 (M.P.)  
Tel. : 0731-2426700, 2426718, 2524003, Fax : 0731-2426726 • CIN : L24233MP1985PLC002709

Date: 13/08/2019

To,  
The Company Secretary,  
Corporate Compliance Department  
The National Stock Exchange of India Limited  
Bandra Kurla Complex, Mumbai

To,  
The Company Secretary  
Corporate Compliance Department  
BSE Limited  
Dalal Street, P.J. Tower, Mumbai

Sub: Submission of Un-audited Financial Results of the Company for quarter ended on 30.06.2019 along with Limited Review Report as per Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Ref: BSE Scrip Code: 524396; NSE Symbol: BIOFILCHEM; ISIN: INE829A01014

Dear Sir/Madam,

Pursuant to the provisions of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation 2015, we are hereby enclosing Un-Audited Financial Results together with Limited Review Report thereon for the quarter 30<sup>th</sup> June 2019 **duly approved by the Board of Directors of the Company at its meeting held today i.e. on Tuesday, 13<sup>th</sup> August, 2019.**

Further, copy of Un-Audited Financial Statements and Limited Review Report shall also be submitted in XBRL mode (Excel Template provided by Exchange) within 24 hours from the conclusion of Board Meeting.

The aforesaid results will be published in one Hindi (vernacular) and widely circulated English Newspaper. The Results shall also be uploaded on website of Stock Exchanges i.e. www.bseindia.com and www.nseindia.com and on the website of the Company at www.biofilgroup.net.

You are requested to take on record the above said financial results for your reference and record.

Yours Faithfully

For Biofil Chemicals and Pharmaceuticals Limited

Ramesh Shah  
Managing Director  
(DIN: 00028819)





Review report to of **Biofil Chemicals and Pharmaceuticals Limited**

We have reviewed the accompanying statement of unaudited financial results of **Biofil Chemicals and Pharmaceuticals Limited** for the period ended 30<sup>th</sup> June 2019. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.


**Place: Indore**

**Date: 13.08.2019**

**For Maheshwari & Gupta**

**Chartered Accountant**

FRN: 006179C



**CA Anil Maheshwari**


**Partner**

**M No.403346**

**UDIN: 19403346AAAADF1906**

( Amount in Lakhs except EPS)

Statement of Standalone Unaudited Financial Results for the quarter ended 30th June 2019					
	Particulars	3 Month Ended	3 Month	3 Month Ended	Year ended
		30/06/2019	Ended	31/03/2019	March 31 2019
		Unaudited	Unaudited	Audited	Audited
I	Revenue from Operation	159.41	422.40	247.44	2312.85
II	Other Income	1.11	1.66	4.44	10.12
III	<b>Total Revenue (I + II)</b>	<b>160.52</b>	<b>424.07</b>	<b>251.89</b>	<b>2322.98</b>
IV	<b>Expenses</b>				
	(a) Cost of materials consumed	86.67	12.29	13.33	77.27
	(b) Purchases of stock-in-trade	25.03	413.14	69.94	1904.95
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(20.73)	(59.39)	57.17	17.04
	(d) Employee benefits expense	18.97	21.19	26.93	89.22
	(e) Finance Cost	3.59	3.86	4.37	16.03
	(f) Depreciation and Amortisation Expense	9.13	7.49	14.48	36.51
	(g) Other expenses	27.19	19.08	52.04	122.12
	<b>Total expenses (IV)</b>	<b>149.86</b>	<b>417.66</b>	<b>238.25</b>	<b>2263.15</b>
V	<b>Profit/ (Loss) before exceptional items and tax (III-IV)</b>	<b>10.67</b>	<b>6.41</b>	<b>13.63</b>	<b>59.83</b>
VI	<b>Exceptional Items</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>
VII	<b>Profit/ (Loss) before tax (V - VI)</b>	<b>10.67</b>	<b>6.41</b>	<b>13.63</b>	<b>59.83</b>
VIII	<b>Tax expense:</b>				
	(1) Current tax	0.00	0.00	11.60	11.60
	(2) Deferred tax Credit/(Charge)	0.00	0.00	0.00	0.00
IX	<b>Profit/(Loss) for the period from continuing operation (VII-VIII)</b>	<b>10.67</b>	<b>6.41</b>	<b>2.04</b>	<b>48.23</b>
X	<b>Profit/(Loss) for the period for dis-continued operation</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>
XI	<b>Tax expenses of discontinued operation</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>
XII	<b>Profit/(Loss) for the period for dis-continued operation after tax (X-XI)</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>
XIII	<b>Profit/ (Loss) for the period (IX+XII)</b>	<b>10.67</b>	<b>6.41</b>	<b>2.04</b>	<b>48.23</b>
XIV	<b>Other Comprehensive Income</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>
	A) (I) Items that will not be reclassified to Profit or Loss	0.00	0.00	0.00	0.00
	(II) Income Tax relating to items that will not be reclassified to Profit or Loss				
	B) (i) Items that will be reclassified to Profit or Loss	0.00	0.00	0.00	0.00
	(II) Income Tax relating to items that will be reclassified to Profit or Loss				
XV	<b>Total Comprehensive Income for the period (XIII + XIV) (Comprising Profit or Loss and other Comprehensive income for the period)</b>	<b>10.67</b>	<b>6.41</b>	<b>2.04</b>	<b>48.23</b>
XVI	<b>Paid-Up equity share capital (face value of Rs 10/- each)</b>	<b>1627.38</b>	<b>1627.38</b>	<b>1627.38</b>	<b>1627.38</b>
XVII	<b>Reserves (Excluding Revaluation Reserve)</b>				<b>-638.63</b>
XVIII	<b>Earnings per equity shares (for continuing operation):</b>				
	(1) Basic (Rs)	0.07	0.04	0.01	0.30
	(2) Diluted (Rs)	0.07	0.04	0.01	0.30



- 1 The above un-audited financial results of the company for the quarter and three month ended June 30, 2019 were reviewed by the Audit committee and approved by the Board of Directors at their meeting held on Aug 13, 2019.
- 2 The Limited Review of the financial Results of the Quarter ended 30th June 2019 pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosures Requirements Regulations 2015, has been carried out by the Statutory Auditors.
- 3 The Company has reported segment wise information as per Indian Accounting Standard (Ind AS-108). The Operations of the Company are conducted within India, there is no separate reportable geographical segment and the company reported the following business segments
  - I. Pharma Product
  - II. Chemicals Division
  - III. Plastic Division
- 4 This statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable.
- 5 The figures of the previous period / year have been re-stated/ re-grouped / re-arranged/ reclassified and / or recasted wherever found necessary.
- 6 The aforesaid un-audited financial Results will be uploaded on the Company's website [www.biofilgroup.net](http://www.biofilgroup.net) and will also be available on the websites of the Stock exchanges i.e. [www.bseindia.com](http://www.bseindia.com) and [www.nseindia.com](http://www.nseindia.com) for the benefit of shareholders and investors
- 7 The figures for the quarter ended 31.03.2019 are the balancing figures between the audited figures in respect of the full financial year and the years to date figures up to the third quarter which were subject to limited review.
- 8 The Company has adopted IND AS 116 "Leases" effective from 01.04.2019 and applied standard to its Leases.


Date : 13-08-2019

Place : Indore

FOR Biofil Chemicals & Pharmaceuticals Limited



**RAMESH SHAH**  
**MANAGING DIRECTOR**  
**( DIN: 00028819)**



**BIOFIL CHEMICALS AND PHARMACEUTICALS LTD.**  
**CIN L24233MP1985PLC002709**

Segmentwise Revenue, Results and Capital Employed for year ended 30 June-2019

(Amount in Lakhs)

S.No.	Segment Revenue	Quarter Ended			Year Ended
		June 30 , 2019	March 31, 2019	June 30 , 2018	31 March 2019
		Reviewed	Audited	Reviewed	Audited
<b>1</b>	<b>Segment Revenue</b>				
	Pharma Unit	55.59	200.90	381.43	2,110.13
	Chemicals Division	103.82	46.55	40.98	202.73
	Plastic Division	0.00	0.00	0.00	0.00
	Other	1.11	2.30	1.66	7.98
	<b>Gross Turnover</b>	<b>160.52</b>	<b>249.75</b>	<b>424.07</b>	<b>2,320.84</b>
<b>2</b>	<b>Segment Results</b>				
	Pharma Unit	8.06	27.80	4.62	63.52
	Chemicals Division	9.73	-4.53	6.69	22.36
	Plastic Division	-3.56	1.25	-1.07	-3.69
	Other	0.00	-8.45	0.00	-8.45
	<b>Total Segment Profit Before Tax</b>	<b>14.23</b>	<b>16.07</b>	<b>10.24</b>	<b>73.72</b>
	Interest Income	0.00	2.14	0.00	2.14
	Interest Expenses	3.56	4.57	3.83	16.03
	Other Unallocable Income net of Expenditure				
	<b>Profit Before Tax</b>	<b>10.67</b>	<b>13.63</b>	<b>6.41</b>	<b>59.83</b>
	Provision for current tax	0.00	11.51	0.00	11.51
	Item Related Earlier Year	0.00	0.09	0.00	0.09
	<b>Profit After Tax</b>	<b>10.67</b>	<b>2.04</b>	<b>6.41</b>	<b>48.23</b>
<b>3</b>	<b>Capital Employed</b>				
	<b>Segment Assets (A)</b>				
	Pharma Division	1,340.63	1,411.32	1,262.13	1,411.32
	Chemicals Division	1,008.90	958.88	878.73	958.88
	Plastic Division	50.05	51.11	59.39	51.11
	Other				
	<b>Total (A)</b>	<b>2,399.58</b>	<b>2,421.30</b>	<b>2,200.26</b>	<b>2,421.30</b>
	<b>Segment Liabilities (B)</b>				
	Pharma Division	735.37	792.75	700.18	792.75
	Chemicals Division	180.20	98.00	31.65	98.00
	Plastic Division	150.79	165.58	162.54	165.58
	Other				
	<b>Total (B)</b>	<b>1,066.35</b>	<b>1,056.33</b>	<b>894.36</b>	<b>1,056.33</b>
	<b>Total Capital Employed (Segment Assets- Segment Liabilities)</b>				
	Pharma Division	605.27	618.56	561.96	618.56
	Chemicals Division	828.70	860.88	847.08	860.88
	Plastic Division	-100.74	-114.48	-103.15	-114.48
	Other	0.00	0.00	0.00	0.00
	<b>Total Capital Employed (Segment Assets- Segment Liabilities)</b>	<b>1,333.23</b>	<b>1,364.97</b>	<b>1,305.89</b>	<b>1,364.97</b>

DATE : 13/08/2019  
PLACE : INDORE

**BIOFIL CHEMICALS AND PHARMACEUTICALS LTD.**  
  
**RAMESH SHAH**  
MANAGING DIRECTOR  
DIN: 00028819

